Creative Planning
DNLI icon

Creative Planning’s Denali Therapeutics DNLI Stock Holding History

Creative Planning’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.18M Buy
84,644
+10,575
+14% +$217K ﹤0.01% 2019
2026
Q1 		$1.42M Buy
74,069
+13,303
+22% +$265K ﹤0.01% 2177
2025
Q4 		$1M Buy
60,766
+5,932
+11% +$100K ﹤0.01% 2278
2025
Q3 		$796K Sell
54,834
-2,844
-5% -$40.9K ﹤0.01% 2337
2025
Q2 		$807K Buy
57,678
+27,114
+89% +$382K ﹤0.01% 2044
2025
Q1 		$416K Sell
30,564
-17,386
-36% -$333K ﹤0.01% 2468
2024
Q4 		$977K Sell
47,950
-12,304
-20% -$315K ﹤0.01% 1656
2024
Q3 		$1.76M Buy
60,254
+17,221
+40% +$427K ﹤0.01% 1146
2024
Q2 		$999K Buy
43,033
+3,458
+9% +$66.4K ﹤0.01% 1401
2024
Q1 		$812K Buy
39,575
+14,765
+60% +$277K ﹤0.01% 1494
2023
Q4 		$532K Buy
24,810
+10,394
+72% +$206K ﹤0.01% 1672
2023
Q3 		$297K Buy
14,416
+215
+2% +$5.45K ﹤0.01% 1955
2023
Q2 		$419K Buy
14,201
+3,853
+37% +$108K ﹤0.01% 1673
2023
Q1 		$238K Buy
10,348
+2,879
+39% +$79.2K ﹤0.01% 1990
2022
Q4 		$208K Buy
7,469
+181
+2% +$5.39K ﹤0.01% 1999
2022
Q3 		$224K Buy
7,288
+213
+3% +$6.92K ﹤0.01% 1834
2022
Q2 		$208K Buy
7,075
+295
+4% +$7.73K ﹤0.01% 1856
2022
Q1 		$218K Buy
6,780
+1,572
+30% +$54.1K ﹤0.01% 1837
2021
Q4 		$232K Hold
5,208
– – ﹤0.01% 1789
2021
Q3 		$263K Buy
+5,208
New +$294K ﹤0.01% 1678
2020
Q4 		– Sell
-11,080
Closed -$397K – 2374
2020
Q3 		$397K Buy
+11,080
New +$334K ﹤0.01% 1255

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Creative Planning's DNLI Position: Q2 2026 in Review

Creative Planning increased its Denali Therapeutics (DNLI) stake by 14% in Q2 2026, buying an estimated $217K and bringing the position to 84,644 shares worth $2.18M. The position accounts for ﹤0.01% of the portfolio, ranked #2019.

Creative Planning first reported a position in DNLI in Q3 2020 and has held it in 21 quarters since. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • Creative Planning held 84,644 shares of Denali Therapeutics worth $2.18M as of Q2 2026.
  • Creative Planning bought 10,575 Denali Therapeutics shares in Q2 2026, an estimated $217K.
  • Denali Therapeutics made up ﹤0.01% of Creative Planning's portfolio in Q2 2026, its #2019 holding.
  • Creative Planning first reported a position in Denali Therapeutics in Q3 2020 and has held it in 21 quarters since.
  • 292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Creative Planning's 13F filing for Q2 2026, filed 13 Aug 2026.